NASEM report offers strategies to make prescription drugs more affordable

Nov 30, 2017 - 09:17 AM

Access to effective and affordable medicines is necessary for public health, social equity, and economic development, but the biopharmaceutical sector is not meeting that need, according to a report released today by the National Academies of Sciences, Engineering, and Medicine. “Our report seeks to address the market failures that currently permeate the biopharmaceutical sector, such as lack of competition due to distortions in the application of the patent protection process, the imbalance between the negotiating power of suppliers and purchasers, and the convoluted structure of the supply chain,” the authors note. The report offers eight recommendations with 27 actions to improve the affordability of prescription drugs without discouraging the development of new and more effective drugs for the future. Among other measures, the report recommends improving methods for assessing the value that drugs provide and ensuring that incentives to develop drugs for rare diseases are not extended to widely sold drugs; taking actions to continually foster greater access to off-patent generic drugs; and discouraging direct-to-consumer advertisements for prescription drugs. 

Related News Articles

Headline
Survey finds voters associate corporate insurers as primary driver of rising healthcare costs
A survey conducted by Morning Consult on behalf of the Coalition to Strengthen America's Healthcare found that 47% of voters believe corporate health insurers…
Headline
Amicus brief seeks to provide relief from Aetna’s ‘level of severity’ policy
The AHA filed an amicus brief June 5 in the U.S. District Court for the Eastern District of Pennsylvania in support of a provider seeking to obtain…
Headline
CMS releases updated report on complaint data, enforcement efforts 
The Centers for Medicare & Medicaid Services has released an updated report on complaint data and enforcement of health insurance market reforms. CMS said…
Headline
Survey finds 1 in 5 privately insured adults reported coverage denials for doctor-recommended care
A survey released June 4 by the Commonwealth Fund on insurance coverage denials found that 1 in 5 privately insured U.S. adults reported that they or a family…
Headline
Eli Lilly moves to deny 340B pricing over data requirements; AHA urges federal action
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.In a statement…
Headline
CMS issues interim final rule on Medicaid community engagement requirements 
The Centers for Medicare & Medicaid Services June 1 issued an interim final rule with comment period implementing the statutory requirement that certain…